Skip to main
OLMA
OLMA logo

Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Olema Pharmaceuticals (OLMA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Olema Pharmaceuticals demonstrates a strong pipeline with promising results from its drug candidates, particularly OP-1250 and palazestrant, which exhibit differentiated efficacy profiles across ESR1 mutant and wild-type patient subtypes. The positive median progression-free survival (mPFS) data of 7.2 months in the Phase 2 study for palazestrant, along with a projected superiority with the combination therapy of palazestrant and ribociclib, suggests the potential for best-in-class status among similar therapies. Upcoming Phase 3 trials target both patient populations, with expectations for updated data in 2025, which may further bolster the company’s market position and financial outlook.

Bears say

Olema Pharmaceuticals faces significant risks that adversely impact its financial outlook, including concerns about the safety and efficacy of its clinical candidates, which could hinder market acceptance and future revenue. Additionally, the company may encounter intensified competition from existing therapies or other drug development programs, further complicating its market position. Furthermore, with a projected cash runway extending only into 2027 and an anticipated need for approximately $600 million in additional financing by 2040, Olema's financial stability remains precarious, coupled with potential regulatory hurdles and intellectual property challenges.

Olema Pharmaceuticals (OLMA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Olema Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Olema Pharmaceuticals (OLMA) Forecast

Analysts have given Olema Pharmaceuticals (OLMA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Olema Pharmaceuticals (OLMA) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Olema Pharmaceuticals (OLMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.